Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
NCT02945852
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
apatinib
Sponsor
Fan Yun, MD